dc.contributor.author | Kaya T.T. | |
dc.contributor.author | Altun A. | |
dc.contributor.author | Turgut N.H. | |
dc.contributor.author | Ataseven H. | |
dc.contributor.author | Koyluoglu G. | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:31:32Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:31:32Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1513-7368 | |
dc.identifier.uri | https://dx.doi.org/10.7314/APJCP.2016.17.3.1103 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/5284 | |
dc.description | Asian Pacific Organization for Cancer Prevention | en_US |
dc.description.abstract | In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29). Real time cell analysis (RTCA, Xcelligence system) was used to determine the effects on colorectal cancer cell proliferation. Apoptosis was assessed with annexin V staining and angiogenesis was determined with chorioallantoic membrane model. We found that motesanib alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Combination with DUP-697 increased the antiproliferative, antiangiogenic and apoptotic effects. Results of this study indicate that motesanib may be a good choice in treatment of colorectal tumors. In addition, the increased effects of combination of motesanib with DuP-697 raise the possibility of using lower doses of these drugs and therefore avoid/minimize the dose-dependent side effects generally observed. | en_US |
dc.description.sponsorship | Turgut, N.H.; Department of Gastroenterology, Cumhuriyet UniversityTurkey; email: nergizht@yahoo.com | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.7314/APJCP.2016.17.3.1103 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Colorectal cancer | en_US |
dc.subject | COX-2 inhibition | en_US |
dc.subject | Motesanib | en_US |
dc.subject | Multikinase inhibitor | en_US |
dc.title | Effects of a multikinase inhibitor motesanib (AMG 706) alone and combined with the selective DuP-697 COX-2 inhibitor on colorectal cancer cells | en_US |
dc.type | article | en_US |
dc.relation.journal | Asian Pacific Journal of Cancer Prevention | en_US |
dc.contributor.department | Kaya, T.T., Department of Pharmacology, Cumhuriyet University, Sivas, Turkey -- Altun, A., Department of Pharmacology, Cumhuriyet University, Sivas, Turkey -- Turgut, N.H., Department of Gastroenterology, Cumhuriyet University, Sivas, Turkey -- Ataseven, H., Department of Pharmacology, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey -- Koyluoglu, G., Department of Pediatric Surgery, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.endpage | 1110 | en_US |
dc.identifier.startpage | 1103 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |